CN106109791A - 一种治疗肝癌的中药组合物及其制备方法 - Google Patents
一种治疗肝癌的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN106109791A CN106109791A CN201610734169.9A CN201610734169A CN106109791A CN 106109791 A CN106109791 A CN 106109791A CN 201610734169 A CN201610734169 A CN 201610734169A CN 106109791 A CN106109791 A CN 106109791A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- chinese medicine
- medicine composition
- cordyceps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title description 7
- 241000190633 Cordyceps Species 0.000 claims abstract description 26
- 108010050181 aleurone Proteins 0.000 claims abstract description 17
- 241000746375 Andrographis Species 0.000 claims abstract description 14
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000008187 granular material Substances 0.000 claims description 10
- 230000029087 digestion Effects 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241000237502 Ostreidae Species 0.000 claims 1
- 235000020636 oyster Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 208000006673 asthma Diseases 0.000 abstract description 7
- 206010006458 Bronchitis chronic Diseases 0.000 abstract description 6
- 206010006451 bronchitis Diseases 0.000 abstract description 6
- 208000007451 chronic bronchitis Diseases 0.000 abstract description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 5
- 206010002091 Anaesthesia Diseases 0.000 abstract description 5
- 201000006306 Cor pulmonale Diseases 0.000 abstract description 5
- 241000196324 Embryophyta Species 0.000 abstract description 5
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 abstract description 5
- 208000004186 Pulmonary Heart Disease Diseases 0.000 abstract description 5
- 230000001154 acute effect Effects 0.000 abstract description 5
- 230000002776 aggregation Effects 0.000 abstract description 5
- 238000004220 aggregation Methods 0.000 abstract description 5
- 230000037005 anaesthesia Effects 0.000 abstract description 5
- 230000000702 anti-platelet effect Effects 0.000 abstract description 5
- 239000003146 anticoagulant agent Substances 0.000 abstract description 5
- 230000001077 hypotensive effect Effects 0.000 abstract description 5
- 230000002107 myocardial effect Effects 0.000 abstract description 5
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 5
- 230000036284 oxygen consumption Effects 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 5
- 230000009993 protective function Effects 0.000 abstract description 5
- 210000002460 smooth muscle Anatomy 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 206010043554 thrombocytopenia Diseases 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 206010003119 arrhythmia Diseases 0.000 abstract description 4
- 230000006793 arrhythmia Effects 0.000 abstract description 4
- 206010014561 Emphysema Diseases 0.000 abstract description 3
- 229960002275 pentobarbital sodium Drugs 0.000 abstract description 2
- 206010047470 viral myocarditis Diseases 0.000 abstract description 2
- 230000001934 delay Effects 0.000 abstract 1
- 206010011224 Cough Diseases 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 201000002481 Myositis Diseases 0.000 description 3
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- XXLFLUJXWKXUGS-UHFFFAOYSA-N 6-methoxyquinoline-4-carboxylic acid Chemical compound N1=CC=C(C(O)=O)C2=CC(OC)=CC=C21 XXLFLUJXWKXUGS-UHFFFAOYSA-N 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- IPQVTOJGNYVQEO-UHFFFAOYSA-N 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical class OC1C(O)C(O)C(CO)OC1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2C1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(OC3C(C(O)C(O)C(CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 201000009663 hepatic tuberculosis Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- UEHVFWBKXUSZEQ-UHFFFAOYSA-N orixine Natural products C1=C2C(OC)=C(CC(O)C(C)(C)O)C(OC)=NC2=C2OCOC2=C1 UEHVFWBKXUSZEQ-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930186851 sennoside Natural products 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一种治疗肝癌的中药组合物,原料为:糊粉、冬虫夏草、白芷、虎杖、穿心莲、山茱萸、牡蛎、半夏、山楂、女贞子和滑石粉;降低心肌耗氧量、改善心肌缺血、抗血小板聚集和抗心律失常,对急性病毒性心肌炎有明显保护作用;采用天然植物,在研究中并没有发现明显的毒副作用,安全性高,易吸收,起效快,使用方便;对血小板减少及血小板超微结构的损伤均有明显的保护作用,对戊巴比妥钠麻醉有明显的降压作用;调节支气管平滑肌,减轻老年慢性支气管炎、哮喘、肺气肿、肺心病等症状,延缓复发时间。
Description
技术领域
本发明涉及一种天然产物中药组合物制剂,尤其涉及一种治疗肝癌的中药组合物及其制备方法。
背景技术
冬虫夏草又名虫草,是我国民间惯用的一种名贵滋补药材,其营养成分高于人参,可入药,也可食用,是上乘的佳肴,具有很高的营养价值。冬虫夏草可以增强机体的免疫力,滋补肝肾,对肝癌、肝癌等有明显的抑制作用。在临床上对肝虚久咳,气喘,肝结核咯血,盗汗,肾虚腰膝酸痛,阳痿遗精,神经衰弱及化疗、放疗后的红细胞下降都有疗效。
冬虫夏草适宜癌症、糖尿病、红斑狼疮、慢性肾炎、老年慢性支气管炎、肺气肿、肺结核、支气管哮喘、咳嗽气短、虚喘咯血者以及白细胞减少、体虚多汗、自汗、盗汗、病后虚弱、久虚不复或衰老体弱、肾气不足、腰膝酸痛、阳痿遗精者食用。
各省市医药、中药组合物、生物医药“十二五”规划显示,大部分省市预计其中药组合物产业增长率在20%-25%之间,部分省市预计在30%以上,少部分省市低于15%。在几大中药组合物重点省市的规划预测中,中药组合物行业的增长率均在20%以上,其中山东省年均增长率或达30%以上,四川、江西分别在25%、23%左右。预测,“十二五”期间中药组合物工业将保持年均12%以上速度的增长,到2015年总产值超过5590亿,但综合各省市的具体规划,预计我国中药组合物行业整体增速高于中医药事业展“十二五”规划的预测,年增长率或可达20%以上,到2015年中药组合物行业工业总产值或将达到7000亿左右。
冬虫夏草是一种药物名,它的外形特别奇特,冬天是虫子,夏天却是草。那么它是怎样从虫子转为草的?夏天一种称为虫草菌的真菌孢子成熟散落后萌发成菌丝钻到蝠蛾的幼虫身体内,吸取幼虫体内的营养。蝠蛾的幼虫躲进土壤中,这时虫草菌长出很多丝状体,称为菌丝体。幼虫由于体内的营养物质被吸完,只剩下僵死的空壳,当然不能变成蝠蛾了。第二年春夏,气温和天气合适,菌丝体从幼虫的口器中长出,伸出地面。顶端略为膨大,外形像根棒,表面有许多小球形孢子。这些孢子可在空气中飞舞传播,草丛里不知又有多少蝠蛾幼虫将成为这些孢子的生活场所。
冬虫夏草中含水分10.85%,脂肪8.50%,粗蛋白25.3%,粗纤维18.55%,碳水化物28.90%,灰分4.80%。脂肪含饱和脂肪酸13.00%,不饱和脂肪酸82.2%。此外,还含虫草酸约7%,是奎宁酸的异构物。又含冬虫夏草素,是一种淡黄色结晶粉末,在试管内能抑制链球菌、鼻疽杆菌、炭疽杆菌、猪出血性败血症杆菌及葡萄状球菌的生长。另含维生素B120.29μg/100g。
国内药品的现实消费市场是城市居民,农村是巨大的潜在市场,医药市场容量还将进一步扩大。中药组合物包括中成药、中药组合物材、中药组合物饮片,其中成药是最重要的组成部分。据《2013-2017年中国中药组合物行业深度调研与投资战略规划分析报告》数据统计,我国有80%以上的城市居民自行购买过中成药。巨大的需求为国内中药组合物行业的进一步发展提供了巨大的空间。
随着社会城市化、科技化、人性化的发展,医疗保健行业得到了蓬勃的发展,越来越多的消费者注重自身的保健,随之而来的是保健药使用量的增加,而随着人性化理念的普及,及新型和谐社会的构成,研究一种治疗肝癌的中药组合物及其制备方法是非常必要的。
很多中草药的疗效不但经受住了长期医疗实践的检验,而且也已被现代科学研究所证实。有些中草药的有效成分和分子结构等也已经全部或部分地研究清楚。例如麻黄平喘的有效成分麻黄碱、常山治疟的有效成分常山碱、女贞子止痛的主要成分四氢掌叶防己碱(女贞子乙素)、黄连和黄柏止痢的主要成分小蘖碱(黄连素)、黄芩抗菌的主要成分黄芩素、大黄泻下的有效成分番泻甙等等。为了保证药物的疗效,中国劳动人民在长期的实践中,对于药物的栽培、采收、加工、炮制、贮藏保管等方面,也都积累了极为丰富的经验。大量事实证明,中国古代汉人劳动人民通过长期实践所积累起来的医药遗产是极为丰富、极为宝贵的。我们应当珍视这个祖国医药学的伟大宝库,努力发掘,加以提高。
发明内容
本发明提供一种治疗肝癌的中药组合物及其制备方法,解决现有西药技术中的毒副作用大,成本高昂,工艺复杂,崩解时间长等技术问题。
本发明采用以下技术方案:一种治疗肝癌的中药组合物,原料按照组份的质量份数配比包括如下:糊粉100份;冬虫夏草6-10份;白芷10-20份;虎杖5-15份;穿心莲4-16份;山茱萸2-10份;牡蛎3-10份;半夏6-14份;山楂1-10份;女贞子10-20份;滑石粉1-5份。
作为本发明的一种优选技术方案:所述原料按照组份的质量份数配比包括如下:糊粉100份;冬虫夏草6份;白芷10份;虎杖5份;穿心莲4份;山茱萸2份;牡蛎3份;半夏6份;山楂1份;女贞子10份;滑石粉1份。
作为本发明的一种优选技术方案:所述原料按照组份的质量份数配比包括如下:糊粉100份;冬虫夏草10份;白芷20份;虎杖15份;穿心莲16份;山茱萸10份;牡蛎10份;半夏14份;山楂10份;女贞子20份;滑石粉5份。
作为本发明的一种优选技术方案:所述原料按照组份的质量份数配比包括如下:糊粉100份;冬虫夏草8份;白芷15份;虎杖10份;穿心莲10份;山茱萸6份;牡蛎7份;半夏10份;山楂4份;女贞子15份;滑石粉3份。
一种制备所述治疗肝癌的中药组合物的方法,步骤为:
第一步:将冬虫夏草、白芷、虎杖、穿心莲、山茱萸、牡蛎、半夏、山楂和女贞子洗净后切块,加水浸煮1-3次得滤液,浓缩得浸膏;
第二步:加入糊粉,再加入水润湿后混合均匀成稠膏;
第三步:将上述稠膏真空干燥后粉碎做成颗粒,控制颗粒的水分在3-5%加入滑石粉混合后压制成片。
本发明所述一种治疗肝癌的中药组合物及其制备方法采用以上技术方案与现有技术相比,具有以下技术效果:1、降低心肌耗氧量、改善心肌缺血、抗血小板聚集和抗心律失常,对急性病毒性心肌炎有明显保护作用;2、采用天然植物,在研究中并没有发现明显的毒副作用,安全性高,易吸收,起效快,使用方便;3、对血小板减少及血小板超微结构的损伤均有明显的保护作用,对戊巴比妥钠麻醉有明显的降压作用;4、调节支气管平滑肌,减轻老年慢性支气管炎、哮喘、肺气肿、肺心病等症状,延缓复发时间,制成片剂,携带使用方便,成本低廉,工艺简单,可以广泛使用。
具体实施方式
下面对本发明的具体实施方式作进一步详细的说明:
实施例1:
第一步:按质量份数配比称取:糊粉100份;冬虫夏草6份;白芷10份;虎杖5份;穿心莲4份;山茱萸2份;牡蛎3份;半夏6份;山楂1份;女贞子10份;滑石粉1份。
第二步:将冬虫夏草、白芷、虎杖、穿心莲、山茱萸、牡蛎、半夏、山楂和女贞子洗净后切块,加水浸煮1次得滤液,浓缩得浸膏。
第三步:加入糊粉,再加入水润湿后混合均匀成稠膏。
第四步:将上述稠膏真空干燥后粉碎做成颗粒,控制颗粒的水分在3-5%加入滑石粉混合后压制成片。
降低心肌耗氧量、改善心肌缺血、抗血小板聚集和抗心律失常,对急性病毒性心肌炎有明显保护作用;采用天然植物,在研究中并没有发现明显的毒副作用,安全性高,易吸收,起效快,使用方便;对血小板减少及血小板超微结构的损伤均有明显的保护作用,对戊巴比妥钠麻醉有明显的降压作用;调节支气管平滑肌,减轻老年慢性支气管炎、哮喘、肺气肿、肺心病等症状,延缓复发时间,肝癌患者每天服食3片,12周后肿瘤状况有所改善,喘嗽患者每天服食3片,20天后喘咳减轻。
实施例2:
第一步:按质量份数配比称取:糊粉100份;冬虫夏草10份;白芷20份;虎杖15份;穿心莲16份;山茱萸10份;牡蛎10份;半夏14份;山楂10份;女贞子20份;滑石粉5份。
第二步:将冬虫夏草、白芷、虎杖、穿心莲、山茱萸、牡蛎、半夏、山楂和女贞子洗净后切块,加水浸煮3次得滤液,浓缩得浸膏。
第三步:加入糊粉,再加入水润湿后混合均匀成稠膏。
第四步:将上述稠膏真空干燥后粉碎做成颗粒,控制颗粒的水分在3-5%加入滑石粉混合后压制成片。
降低心肌耗氧量、改善心肌缺血、抗血小板聚集和抗心律失常,对急性病毒性心肌炎有明显保护作用;采用天然植物,在研究中并没有发现明显的毒副作用,安全性高,易吸收,起效快,使用方便;对血小板减少及血小板超微结构的损伤均有明显的保护作用,对戊巴比妥钠麻醉有明显的降压作用;调节支气管平滑肌,减轻老年慢性支气管炎、哮喘、肺气肿、肺心病等症状,延缓复发时间,肝癌患者每天服食3片,11周后肿瘤状况有所改善,喘嗽患者每天服食3片,15天后喘咳减轻。
实施例3:
第一步:按质量份数配比称取:糊粉100份;冬虫夏草8份;白芷15份;虎杖10份;穿心莲10份;山茱萸6份;牡蛎7份;半夏10份;山楂4份;女贞子15份;滑石粉3份。
第二步:将冬虫夏草、白芷、虎杖、穿心莲、山茱萸、牡蛎、半夏、山楂和女贞子洗净后切块,加水浸煮2次得滤液,浓缩得浸膏。
第三步:加入糊粉,再加入水润湿后混合均匀成稠膏。
第四步:将上述稠膏真空干燥后粉碎做成颗粒,控制颗粒的水分在3-5%加入滑石粉混合后压制成片。
降低心肌耗氧量、改善心肌缺血、抗血小板聚集和抗心律失常,对急性病毒性心肌炎有明显保护作用;采用天然植物,在研究中并没有发现明显的毒副作用,安全性高,易吸收,起效快,使用方便;对血小板减少及血小板超微结构的损伤均有明显的保护作用,对戊巴比妥钠麻醉有明显的降压作用;调节支气管平滑肌,减轻老年慢性支气管炎、哮喘、肺气肿、肺心病等症状,延缓复发时间,肝癌患者每天服食3片,10周后肿瘤状况有所改善,喘嗽患者每天服食3片,14天后喘咳减轻。
Claims (5)
1.一种治疗肝癌的中药组合物,其特征在于:原料按照组份的质量份数配比包括如下:糊粉100份;冬虫夏草6-10份;白芷10-20份;虎杖5-15份;穿心莲4-16份;山茱萸2-10份;牡蛎3-10份;半夏6-14份;山楂1-10份;女贞子10-20份;滑石粉1-5份。
2.根据权利要求1所述的一种治疗肝癌的中药组合物,其特征在于:原料按照组份的质量份数配比包括如下:糊粉100份;冬虫夏草6份;白芷10份;虎杖5份;穿心莲4份;山茱萸2份;牡蛎3份;半夏6份;山楂1份;女贞子10份;滑石粉1份。
3.根据权利要求1所述的一种治疗肝癌的中药组合物,其特征在于:原料按照组份的质量份数配比包括如下:糊粉100份;冬虫夏草10份;白芷20份;虎杖15份;穿心莲16份;山茱萸10份;牡蛎10份;半夏14份;山楂10份;女贞子20份;滑石粉5份。
4.根据权利要求1所述的一种治疗肝癌的中药组合物,其特征在于:原料按照组份的质量份数配比包括如下:糊粉100份;冬虫夏草8份;白芷15份;虎杖10份;穿心莲10份;山茱萸6份;牡蛎7份;半夏10份;山楂4份;女贞子15份;滑石粉3份。
5.一种制备权利要求1所述的治疗肝癌的中药组合物的方法,其特征在于步骤为:
第一步:将冬虫夏草、白芷、虎杖、穿心莲、山茱萸、牡蛎、半夏、山楂和女贞子洗净后切块,加水浸煮1-3次得滤液,浓缩得浸膏;
第二步:加入糊粉,再加入水润湿后混合均匀成稠膏;
第三步:将上述稠膏真空干燥后粉碎做成颗粒,控制颗粒的水分在3-5%加入滑石粉混合后压制成片。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610734169.9A CN106109791A (zh) | 2016-08-26 | 2016-08-26 | 一种治疗肝癌的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610734169.9A CN106109791A (zh) | 2016-08-26 | 2016-08-26 | 一种治疗肝癌的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106109791A true CN106109791A (zh) | 2016-11-16 |
Family
ID=57274653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610734169.9A Withdrawn CN106109791A (zh) | 2016-08-26 | 2016-08-26 | 一种治疗肝癌的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106109791A (zh) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1113779A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 抗乙肝制剂 |
CN1209333A (zh) * | 1997-08-22 | 1999-03-03 | 王万锁 | 一种治疗癌症的药物及其制备方法 |
CN1233483A (zh) * | 1998-04-30 | 1999-11-03 | 高云渌 | 一种治疗肝硬化、肝癌的药物 |
CN1300623A (zh) * | 1999-12-20 | 2001-06-27 | 张发平 | 一种中成药 |
CN1486737A (zh) * | 2003-08-27 | 2004-04-07 | 李文侠 | 治疗肝病的“四效合一”中药方剂 |
CN1839958A (zh) * | 2006-01-10 | 2006-10-04 | 张承昌 | 治疗癌症的药物及其生产方法 |
CN101934025A (zh) * | 2010-08-18 | 2011-01-05 | 赵全会 | 一种用于清热解毒的中药 |
CN101972448A (zh) * | 2010-10-15 | 2011-02-16 | 林万硕 | 一种用于治疗肝癌的中药组合物 |
CN102805836A (zh) * | 2011-05-31 | 2012-12-05 | 上海中医药大学附属龙华医院 | 一种治疗原发性肝癌的中药组合物及其制备方法 |
CN103191267A (zh) * | 2013-04-25 | 2013-07-10 | 崔新明 | 一种治疗肝癌的中药组合物 |
CN105233188A (zh) * | 2015-11-24 | 2016-01-13 | 江崇礼 | 一种用于治疗肝癌的中药组合物及其用途 |
CN105380265A (zh) * | 2015-11-06 | 2016-03-09 | 劲膳美生物科技股份有限公司 | 肝癌医学配方食品 |
-
2016
- 2016-08-26 CN CN201610734169.9A patent/CN106109791A/zh not_active Withdrawn
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1113779A (zh) * | 1994-06-17 | 1995-12-27 | 殷广全 | 抗乙肝制剂 |
CN1209333A (zh) * | 1997-08-22 | 1999-03-03 | 王万锁 | 一种治疗癌症的药物及其制备方法 |
CN1233483A (zh) * | 1998-04-30 | 1999-11-03 | 高云渌 | 一种治疗肝硬化、肝癌的药物 |
CN1300623A (zh) * | 1999-12-20 | 2001-06-27 | 张发平 | 一种中成药 |
CN1486737A (zh) * | 2003-08-27 | 2004-04-07 | 李文侠 | 治疗肝病的“四效合一”中药方剂 |
CN1839958A (zh) * | 2006-01-10 | 2006-10-04 | 张承昌 | 治疗癌症的药物及其生产方法 |
CN101934025A (zh) * | 2010-08-18 | 2011-01-05 | 赵全会 | 一种用于清热解毒的中药 |
CN101972448A (zh) * | 2010-10-15 | 2011-02-16 | 林万硕 | 一种用于治疗肝癌的中药组合物 |
CN102805836A (zh) * | 2011-05-31 | 2012-12-05 | 上海中医药大学附属龙华医院 | 一种治疗原发性肝癌的中药组合物及其制备方法 |
CN103191267A (zh) * | 2013-04-25 | 2013-07-10 | 崔新明 | 一种治疗肝癌的中药组合物 |
CN105380265A (zh) * | 2015-11-06 | 2016-03-09 | 劲膳美生物科技股份有限公司 | 肝癌医学配方食品 |
CN105233188A (zh) * | 2015-11-24 | 2016-01-13 | 江崇礼 | 一种用于治疗肝癌的中药组合物及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103141679B (zh) | 一种含中草药的复合型羊饲料 | |
CN103141683B (zh) | 一种含中草药的复合型猪饲料 | |
CN103585261A (zh) | 玛咖人参片及其制备方法 | |
WO2012089175A2 (zh) | 一种以微生物发酵法炮制的茶剂中药 | |
KR100939906B1 (ko) | 한방 추출액을 이용한 어류 양식용 사료첨가제 | |
CN105077232A (zh) | 一种铁皮石斛枸杞胶囊及其制备方法 | |
CN106692675A (zh) | 一种养气活血的膏滋及其制备方法和应用 | |
CN101371720B (zh) | 烟草添加剂及其制备方法和应用 | |
CN106343489A (zh) | 一种纯天然植物配方的黑花生的加工方法 | |
CN101006816A (zh) | 枸杞四珍袋泡茶及其制备工艺 | |
CN104666928A (zh) | 一种铁皮石斛菊花快速饮片制备方法 | |
CN104522661A (zh) | 含金银花提取物的保健含片及其生产方法 | |
CN105482965A (zh) | 一种养生保健酒及其制备方法 | |
KR101028073B1 (ko) | 혈액순환을 개선하여 신체 각 부위를 활성화 시키며 면역력을 증진시키는 작용 및 기전을 가진 조성물과 그 제조방법 | |
CN106508423A (zh) | 利用药食同源材料培育复合多营养黑木耳的生产方法 | |
CN106109791A (zh) | 一种治疗肝癌的中药组合物及其制备方法 | |
CN106942507A (zh) | 一种防病鹅饲料及其制备方法 | |
CN107223736A (zh) | 一种酸枣玉竹茶的制备方法 | |
CN105230708A (zh) | 一种玉竹刺角瓜面包的制作方法 | |
CN106074986A (zh) | 一种治疗肺癌的中药组合物及其制备方法 | |
CN106214971A (zh) | 一种补肾的中药组合物及其制备方法 | |
CN114344434B (zh) | 一种治疗肺结节的中药组合物及其制备方法 | |
CN103734593B (zh) | 一种复合西洋参米健康食品的生产工艺 | |
CN108432968A (zh) | 一种用于改善獭兔毛皮品质的饲料添加剂及其制备方法 | |
CN106675962A (zh) | 一种西洋参五味子酒及其制作方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161116 |
|
WW01 | Invention patent application withdrawn after publication |